Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial.

However, as 95% CI crossed zero, this reduction did not reach statistical significance ( Table 3 ).

also in 111,027 other papers

Notably, a decreasing trend in muscle mass was observed exclusively in the Dapa group, with a significant reduction in the skeletal muscle index (SMI) ( Table 4 ). 3.4 Safety evaluation Adverse events were observed in six patients in the Dapa group and in three in the Vit E group.

also in 47,180 other papers